Last reviewed · How we verify
Bemiparina
At a glance
| Generic name | Bemiparina |
|---|---|
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Intrauterine Growth Restriction With Low Molecular Heparin. (PHASE3)
- Comparison of Two Different Doses of Bemiparin in COVID-19 (PHASE3)
- Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding. (PHASE4)
- Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bemiparina CI brief — competitive landscape report
- Bemiparina updates RSS · CI watch RSS
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau portfolio CI